A randomized phase II study comparing erlotinib (E) versus E alternating with chemotherapy in relapsed non-small cell lung cancer (NSCLC) patients. The NVALT10 …
JG Aerts, H Codrington, S Burgers… - Annals of …, 2012 - annalsofoncology.org
Introduction Epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) administered
concurrently with chemotherapy did not improve outcome. However, in preclinical models …
concurrently with chemotherapy did not improve outcome. However, in preclinical models …
A Randomized Phase II Study Comparing Erlotinib (E) Versus e Alternating with Chemotherapy in Relapsed Non-Small Cell Lung Cancer (NSCLC) Patients. The …
JG Aerts, H Codrington, S Burgers, B Biesma… - Annals of …, 2012 - Elsevier
Introduction Epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) administered
concurrently with chemotherapy did not improve outcome. However, in preclinical models …
concurrently with chemotherapy did not improve outcome. However, in preclinical models …